152 related articles for article (PubMed ID: 18440306)
1. SH3BP2 is an activator of NFAT activity and osteoclastogenesis.
Lietman SA; Yin L; Levine MA
Biochem Biophys Res Commun; 2008 Jul; 371(4):644-8. PubMed ID: 18440306
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
3. Decreased SH3BP2 inhibits osteoclast differentiation and function.
Kawamoto T; Fan C; Gaivin RJ; Levine MA; Lietman SA
J Orthop Res; 2011 Oct; 29(10):1521-7. PubMed ID: 21448930
[TBL] [Abstract][Full Text] [Related]
4. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
5. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption.
Kim MS; Day CJ; Selinger CI; Magno CL; Stephens SR; Morrison NA
J Biol Chem; 2006 Jan; 281(2):1274-85. PubMed ID: 16280328
[TBL] [Abstract][Full Text] [Related]
6. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
[TBL] [Abstract][Full Text] [Related]
8. The calcineurin inhibitor tacrolimus as a new therapy in severe cherubism.
Kadlub N; Vazquez MP; Galmiche L; L'Herminé AC; Dainese L; Ulinski T; Fauroux B; Pavlov I; Badoual C; Marlin S; Deckert M; Leboulanger N; Berdal A; Descroix V; Picard A; Coudert AE
J Bone Miner Res; 2015 May; 30(5):878-85. PubMed ID: 25491283
[TBL] [Abstract][Full Text] [Related]
9. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
10. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
11. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase.
Fretz JA; Shevde NK; Singh S; Darnay BG; Pike JW
Mol Endocrinol; 2008 Mar; 22(3):737-50. PubMed ID: 18063694
[TBL] [Abstract][Full Text] [Related]
13. Identification of two-pore channel 2 as a novel regulator of osteoclastogenesis.
Notomi T; Ezura Y; Noda M
J Biol Chem; 2012 Oct; 287(42):35057-35064. PubMed ID: 22833668
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
15. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of osteoclastogenesis by 6-[10'(Z)-heptadecenyl] salicylic acid from Syzygium tetragonum Wall via preventing nuclear translocation of NFATc1.
Zhang XW; Zhou C; Zhu HD; Shao W; You Y; Peng J; Yin S; Shen X
Phytomedicine; 2014 Jun; 21(7):960-5. PubMed ID: 24703325
[TBL] [Abstract][Full Text] [Related]
17. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
18. Honokiol inhibits osteoclast differentiation and function in vitro.
Hasegawa S; Yonezawa T; Ahn JY; Cha BY; Teruya T; Takami M; Yagasaki K; Nagai K; Woo JT
Biol Pharm Bull; 2010; 33(3):487-92. PubMed ID: 20190414
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes.
Hirata K; Taki H; Shinoda K; Hounoki H; Miyahara T; Tobe K; Ogawa H; Mori H; Sugiyama E
Biol Pharm Bull; 2010; 33(1):133-7. PubMed ID: 20045951
[TBL] [Abstract][Full Text] [Related]
20. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
